A national survey of oncologist and chest physicians' attitudes towards empirical anti-oestrogen therapy, early pleurodesis and preference of sclerosing agents in malignant breast and ovarian pleural disease [1]

Palliative Medicine

Volumn 19, Issue 5, 2005, Pages 430-431

  Medford, Andrew R L ^a   Maskell, Nick A ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; BLEOMYCIN; DOXYCYCLINE; TETRACYCLINE;

BREAST CANCER; CANCER CLASSIFICATION; CONFIDENCE INTERVAL; FEMALE; HEALTH SURVEY; HUMAN; LETTER; MEDICAL PRACTICE; OVARY CANCER; PHYSICIAN ATTITUDE; PLEURA DISEASE; PLEURA EFFUSION; PLEURODESIS; PRACTICE GUIDELINE; PRESCRIPTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ATTITUDE OF HEALTH PERSONNEL; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HEALTH CARE SURVEYS; HUMANS; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; TALC;

EID: 23844481553     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216305pm1033xx     Document Type: Letter

References (5)

1. Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58: ii29-38.
2. Lee YC, Lane KB, Zoia O, Thompson PJ, Light RW, Blackwell TS. Transforming growth factor-beta induces collagen synthesis without inducing IL-8 production in mesothelial cells. Eur Respir J 2003; 22: 197-202.
3. Barbetakis N, Vassiliadis M, Kaplanis K, Valeri R, Tsilikas C. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. BMC Palliative Care 2004; 3: 4-9.
4. Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer World J Surg Oncol 2004; 2: 16-22.
5. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377-82.